What is this study evaluating?

The UC Davis Neuroimmunology Group is conducting a two-year-long phase III trial, called FREEDOMS II, to study the effectiveness and safety of an oral medication for the treatment of relapsing-remitting multiple sclerosis, the most common form of the disease.

What is multiple sclerosis?

Multiple sclerosis is a chronic, progressive, potentially disabling autoimmune disease that attacks the central nervous system. It affects over 2 million people and is the leading cause of neurological disability in young adults. Most currently approved therapies require regular injections and have associated side effects such as injection-site reactions or flu-like symptoms.

Who can join this trial?

• Men and women ages 18 to 55 years
  
  
• Diagnosis of relapsing-remitting MS
  
  
• Not currently on treatment for MS
  
  
• Able to walk without aid

What is required?

Study participants have a two-thirds chance of being on one of two doses of active medication, and a one-third chance of receiving a placebo. During the study, participants will take the medication or placebo daily for 24 months.

Principal Investigator

Mark Agius, M.D., Professor of Neurology

For more information please contact Janelle Butters at (916) 734-6276. More information also is available at http://clinicaltrials.gov/.